Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.73 |
| ▸ | MEN1 | O00255 | 4/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.64 |
| ▸ | HPGD | P15428 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | PLEC | Q15149 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.57 |
| ▸ | KDM5A | P29375 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MPI | P34949 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL265111 | 0.85 | TSHR (1.00) | TSHRMEN1KMT2AHPGDHTT | |
| SCHEMBL31384289 | 0.85 | TSHR (1.00) | TSHRMEN1KMT2AHPGDHTT | |
| SCHEMBL21247799 | 0.84 | HPGD (0.59) | TSHRMEN1KMT2AHPGDALDH1A1 | |
| SCHEMBL11279279 | 0.82 | MPI (0.73) | TSHRMEN1KMT2AHPGDALDH1A1 | |
| SCHEMBL20945141 | 0.82 | TSHR (0.73) | TSHRMEN1KMT2AHPGDHTT | |
| SCHEMBL28666827 | 0.82 | TSHR (0.73) | TSHRMEN1KMT2AHPGDALDH1A1 | |
| SCHEMBL30471655 | 0.82 | TSHR (0.73) | TSHRMEN1KMT2AHPGDHTT | |
| SCHEMBL30540389 | 0.82 | TSHR (0.73) | TSHRMEN1KMT2AHPGDALDH1A1 | |
| SCHEMBL29552755 | 0.82 | MPI (0.73) | TSHRMEN1KMT2AHPGDALDH1A1 | |
| SCHEMBL4063980 | 0.78 | TSHR (0.72) | TSHRMEN1KMT2AHPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4861778-A | 2,3-dihydrophthalazine-1,4-diones | RESEARCH CORPORATION (US) | 1989-08-29 | — | — | US | claimed |
| EP-1794148-B1 | NOVEL PHTHALAZINONE DERIVATIVES, AS AURORA-A KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2009-04-15 | — | — | EP | disclosed |
| US-7501410-B2 | Methods of inhibiting BTK and SYK protein kinases | ROCHE PALO ALTO LLC (US) | 2009-03-10 | — | — | US | disclosed |
| EP-1998777-A1 | METHODS OF INHIBITING BTK AND SYK PROTEIN KINASES | F. Hoffmann-La Roche AG (CH) | 2008-12-10 | — | — | EP | disclosed |
| WO-2007107469-A1 | METHODS OF INHIBITING BTK AND SYK PROTEIN KINASES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-09-27 | — | — | WO | disclosed |
| US-20070219195-A1 | e.g. 4-(5-Methyl-2H-pyrazole-3-ylamino)-phenyl-2H-phthalazin-1-one2-Phenyl-2,3-dihydro-phthalazine-1,4-dione; tyrosine kinase inhibitor; antiinflammatory agent; asthma, rheumatoid arthritis, systemic lupus erythematosus or multiple sclerosis | ROCHE PALO ALTO LLC | 2007-09-20 | — | — | US | disclosed |
| EP-1794148-A1 | NOVEL PHTHALAZINONE DERIVATIVES, AS AURORA-A KINASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-06-13 | — | — | EP | disclosed |
| US-7226923-B2 | Phthalazinone derivatives | HOFFMAN-LA ROCHE INC. (US) | 2007-06-05 | — | — | US | disclosed |
| US-20060089359-A1 | Phthalazinone derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2006-04-27 | — | — | US | disclosed |
| WO-2006032518-A1 | NOVEL PHTHALAZINONE DERIVATIVES, AS AURORA-A KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-03-30 | — | — | WO | disclosed |
| US-4861778-A | 2,3-dihydrophthalazine-1,4-diones | RESEARCH CORPORATION (US) | 1989-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089359-A1 | Phthalazinone derivatives | SDHA, SDHB, CYP3A5 | TSHR 4156/4885MEN1 657/4885KMT2A 2955/4885 |
| US-20070219195-A1 | e.g. 4-(5-Methyl-2H-pyrazole-3-ylamino)-phenyl-2H-phthalazin-1-one2-Phenyl-2,3-dihydro-phthalazine-1,4-dione; tyrosine kinase inhibitor; antiinflammatory agent; asthma, rheumatoid arthritis, systemic lupus erythematosus or multiple sclerosis | SYK, BTK, LCK | TSHR 2375/4885MEN1 3550/4885KMT2A 410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.